Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug-induced metabolic remodeling of immune cell repertoire generates an effective broad-range antimicrobial effect.

Research square·2025
Same author

Genome-wide analysis of Smad and Schnurri transcription factors in <i>C. elegans</i> demonstrates widespread interaction and a function in collagen secretion.

eLife·2025
Same author

Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis.

Diabetes & metabolism·2025
Same author

Genome-wide analysis of Smad and Schnurri transcription factors in <i>C. elegans</i> demonstrates widespread interaction and a function in collagen secretion.

bioRxiv : the preprint server for biology·2024
Same author

Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis.

BMC endocrine disorders·2024
Same author

Glucose ingestion does not lower testosterone concentrations in men on testosterone therapy.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2024

Related Experiment Videos

Exenatide exerts a potent antiinflammatory effect.

Ajay Chaudhuri1, Husam Ghanim, Mehul Vora

  • 1Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, Buffalo, New York 14209, USA.

The Journal of Clinical Endocrinology and Metabolism
|October 21, 2011
PubMed
Summary

Exenatide demonstrated a rapid anti-inflammatory effect by reducing inflammatory markers and gene expression in patients with type 2 diabetes. This effect was observed at the cellular and molecular levels, independent of weight loss.

Related Experiment Videos

Area of Science:

  • Endocrinology and Metabolism
  • Immunology
  • Pharmacology

Background:

  • Inflammation plays a critical role in the pathogenesis of type 2 diabetes and its complications.
  • Exenatide, a glucagon-like peptide-1 receptor agonist, is used for type 2 diabetes management.
  • Potential anti-inflammatory properties of exenatide warrant investigation.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of exenatide in patients with type 2 diabetes.
  • To assess changes in inflammatory markers and cellular pathways following exenatide treatment.

Main Methods:

  • A prospective, randomized, placebo-controlled study involving 24 patients with type 2 diabetes.
  • Patients received exenatide (10 μg twice daily) or placebo for 12 weeks.
  • Fasting blood samples were analyzed for inflammatory markers, gene expression, and cellular responses.

Main Results:

  • Exenatide significantly reduced fasting blood glucose, HbA1c, and free fatty acids.
  • A notable decrease in reactive oxygen species generation and nuclear factor-κB binding was observed.
  • Exenatide suppressed mRNA expression of key inflammatory cytokines (TNFα, IL-1β) and signaling molecules (JNK-1, TLRs, SOCS-3).
  • Plasma levels of MCP-1, MMP-9, SAA, and IL-6 were also reduced.

Conclusions:

  • Exenatide exerts a rapid and significant anti-inflammatory effect at both cellular and molecular levels.
  • The anti-inflammatory action of exenatide is independent of weight loss.
  • These findings suggest a potential anti-atherogenic benefit of exenatide therapy.